FDA Eyes Heart Risks Of Proposed Lundbeck Drug
Officials at the U.S. Food and Drug Administration have expressed concern about a risk of cardiac arrhythmia and death associated with Danish drugmaker H. Lundbeck A/S's proposed schizophrenia drug Serdolect....To view the full article, register now.
Already a subscriber? Click here to view full article